CommercialPrior AuthMedium impact
Human Chorionic Gonadotropin (hCG) (CPB 1081, reviewed 2026-10-08)
Aetna·OB-GYN, Endocrinology, Urology·Medical Policy
We identified it
Oct 10, 2026
Summary
Aetna's hCG policy (CPB 1081, reviewed 2026-10-08) establishes medical necessity criteria for human chorionic gonadotropin coverage across commercial medical plans. The policy requires precertification for all hCG products, covers four specific indications (ART/ovulation induction, prepubertal cryptorchidism, hypogonadotropic hypogonadism, and steroid-refractory GVHD), and designates all other uses as experimental/investigational. This is an existing policy statement with no change effective date indicated.
Action Required
Billing team should verify current implementation of Aetna's precertification requirement for all hCG products (Novarel, Pregnyl, Ovidrel, generic chorionic gonadotropin) by contacting (866) 782-2779 or faxing (860) 754-2515 before claims submission. Confirm that the practice's billing system enforces the four covered indications and denies claims for experimental uses (idiopathic male infertility, microphallus, obesity/weight loss, sole FET endometrium preparation). For infertility ART drugs, verify whether the member's plan requires medical necessity review by Specialty Pharmacy Guideline Management or if approval of the infertility procedure bypasses this review. Document medical authorization numbers and procedure approval confirmations in the patient record prior to billing to prevent claim denials.